Inositol Derivatives with Anti-Inflammatory Activity from Leaves of Solanum capsicoides Allioni

Yan Liu, Xin Meng, Han Wang, Yan Sun, Si-Yi Wang, Yi-Kai Jiang, Adnan Mohammed Algradi, Anam Naseem, Hai-Xue Kuang * and Bing-You Yang *

Key Laboratory of Basic and Application Research of Beiyao, Heilongjiang University of Chinese Medicine, Ministry of Education, Harbin 150040, China
* Correspondence: hxkuang@yahoo.com (H.-X.K.); ybywater@163.com (B.-Y.Y.)

Abstract: Eight new inositol derivatives, solsurinositols A–H (1–8), were isolated from the 70% EtOH extract of the leaves of Solanum capsicoides Allioni. Careful isolation by silica gel column chromatography followed by preparative high-performance liquid chromatography (HPLC) allowed us to obtain analytically pure compounds 1–8. They shared the same relative stereochemistry on the ring but have different acyl groups attached to various hydroxyl groups. This was the first time that inositol derivatives have been isolated from this plant. The chemical structures of compounds 1–8 were characterized by extensive 1D nuclear magnetic resonance (NMR) and 2D NMR and mass analyses. Meanwhile, the in vitro anti-inflammatory activity of all compounds was determined using lipopolysaccharide (LPS)-induced BV2 microglia, and among the isolates, compounds 5 (IC_{50} = 11.21 ± 0.14 µM) and 7 (IC_{50} = 14.5 ± 1.22 µM) were shown to have potential anti-inflammatory activity.

Keywords: inositols; anti-inflammatory activities; Solanum capsicoides; Solanaceae

1. Introduction

Inositols are abundant in the brain and other mammalian tissues, and can be defined as polyols or cyclitols, having the basic structure of one cyclohexane with a hydroxy group bound to each carbon atom of the hexane ring [1]. The study showed that inositol, inositol lipids, and inositol phosphates have become universal constituents of eukaryotes [2]. Inositols and their derivatives were extracted and isolated from Asteraceae, Dioscoreaceae, Amaranthaceae, and Solanaceae, et al. in [3]. Another study showed that myo-inositol plays a positive function in follicular maturity in human follicular fluids and is a marker of good-quality oocytes. These findings prompted the idea that inositol plays an essential role in human reproduction [4]. In addition, myo-inositol dietary supplementation was shown to improve insulin sensitivity, which suggests that inositol plays a potential role in metabolism [5]. Therefore, it is necessary to study inositols and their derivatives.

Solanum capsicoides Allioni (S. capsicoides), one of the members of Solanaceae, has been used in traditional Chinese medicine. It has been recorded as being widely used in China, India, and South America in classical medical books. Modern pharmacological studies have shown that the aerial parts of S. capsicoides have antihypertensive and antidepressant-like effects [6,7]. Their extracts exhibited anti-inflammatory and analgesic effects in [8,9]. Currently, research on the chemical compositions of this plant has revealed the presence of withanolides, steroidal alkaloids, steroidal saponins, and phenylpropanoids [10–14]. However, there have been no reports on inositols from S. capsicoides.

In this study, we further explored the active component from the leaves of S. capsicoides, and eight inositol derivatives were isolated for the first time using different chromatographic techniques. The in vitro activity study found that the crude extract of the leaves of S. capsicoides exhibit anti-inflammatory activity [8], and at the same time, inositols have a
beneficial effect on LPS-induced inflammatory responses in microglial cells [15]. We were inspired to evaluate the in vitro anti-inflammatory activity of isolated compounds using LPS-induced microglia.

2. Results and Discussion

The 70% ethanol extract from the leaves of *S. capsicoides* obtained hitherto unreported solsurinositols A–H (1–8), separated by chromatography (Figure 1), the spectrogram information can see Electronic Supplementary Material (Figures S1–S65).

**Figure 1.** Chemical structures of compounds 1–8.

Compound 1 was obtained as a colorless solid. Its molecular formula, C\textsubscript{22}H\textsubscript{36}O\textsubscript{10}, was determined by positive HR-ESI-MS at m/z 478.2656 [M + NH\textsubscript{4}]\textsuperscript{+} (calcd. 478.2652) with five degrees of unsaturation. The \textsuperscript{13}C NMR and DEPT spectra (Table 1) showed signals at δC 72.5, 71.0, 69.8, 72.3, 72.3, and 73.9 for six oxygenated carbon atoms; four sets of carbonyl signals at δC 171.2, 177.2, 177.5, and 177.8; three methenyl carbons at δC 42.5, 42.6, and 35.1; two methylene carbons at δC 27.8 and 27.9; seven methyl groups at δC 11.9, 11.9, 17.0, 17.3, 19.1, 19.3, and 20.6. The \textsuperscript{1}H NMR spectrum (Table 2) showed six oxygenated protons at δH 5.34 (1H, t, J = 7.4 Hz), 2.41 (1H, q, J = 7.0 Hz), 4.89 (1H, dd, J = 10.0, 2.8 Hz), 3.54 (1H, t, J = 10.0 Hz); seven methyl groups at δH 0.89 (3H, t, J = 7.4 Hz), 0.98 (3H, t, J = 7.4 Hz), 1.20 (3H, d, J = 7.0 Hz), 1.12 (3H, dd, J = 12.2, 7.0 Hz), 1.13 (3H, d, J = 7.0 Hz), 1.13 (3H, d, J = 7.0 Hz), and 1.90 (3H, s); three methine protons; two methylene protons. Compared with the literature (compound “Myo-Inositol pentabenzoate and Myo-inositol”) [16,17], the above data identified the inositol ring structure, and the difference here was that the new compound showed substituent groups.
Table 1. The 600 MHz 1H-NMR data of compounds 1–8 (in CD3OD δ in ppm, J in Hz).

| Position | 1         | 2         | 3         | 4         | 5         | 6         | 7         | 8         |
|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| 1        | 5.34 (t, 10.0) | 5.33 (t, 10.0) | 5.41 (td, 10.0, 5.2) | 5.43 (t, 10.0) | 3.85 (t, 10.1) | 3.78 (t, 9.7) | 5.30 (t, 10.0) | 3.44 (t, 10.0) |
| 2        | 5.06 (dd, 10.0, 2.8) | 5.08 (dd, 10.0, 2.8) | 5.15 (dt, 10.0, 2.8) | 5.16 (ddd, 13.4, 10.0, 2.8) | 4.83 (overlap) | 4.83 (overlap) | 4.92 (dd, 10.0, 2.8) | 5.50 (t, 2.8) |
| 3        | 5.56 (t, 2.8) | 5.55 (t, 2.8) | 5.60 (td, 2.8) | 5.60 (t, 2.8) | 5.51 (t, 2.5) | 5.53 (t, 2.8) | 5.48 (t, 2.8) | 4.96 (dd, 10.0, 2.8) |
| 4        | 4.89 (dd, 10.0, 2.8) | 4.89 (overlap) | 5.15 (dt, 10.0, 2.8) | 5.16 (ddd, 13.4, 10.0, 2.8) | 3.69 (overlap) | 4.81 (overlap) | 3.44 (t, 10.0) | 5.32 (t, 10.0) |
| 5        | 3.84 (t, 10.0) | 3.84 (t, 10.0) | 5.41 (td, 10.0, 5.2) | 5.38 (t, 10.0) | 3.69 (overlap) | 3.75 (overlap) | 3.67 (overlap) | 3.66 (overlap) |
| 6        | 3.54 (t, 10.0) | 3.56 (t, 10.0) | 3.79 (t, 10.0) | 3.79 (t, 10.0) | 4.88 (overlap) | 3.36 (overlap) | 3.67 (overlap) | 3.66 (overlap) |
| 2MB-2    | 2.41 (q, 7.0) | 2.51 (m) | 2.27 (m) | 2.39 (m) | 2.33 (m) | 2.36 (m) | 2.52 (m) | 2.37 (q, 7.0) |
| 2MB-3    | 1.46 (m) | 1.71 (m) | 1.43 (m) | 1.61 (m) | 1.47 (m) | 1.68 (m) | 1.41 (m) | 1.70 (m) |
| 2MB-4    | 0.89 (t, 7.4) | 0.98 (t, 7.4) | 0.84 (t, 7.4) | 0.92 (t, 7.4) | 0.96 (t, 7.4) | 0.85 (t, 7.4) | 0.99 (t, 7.4) | 0.92 (t, 7.5) |
| 2MB-5    | 1.12 (dd, 12.2, 7.0) | 1.20 (d, 7.0) | 1.05 (d, 7.0) | 1.10 (d, 7.0) | 1.18 (d, 7.0) | 1.11 (d, 7.0) | 1.17 (d, 7.0) | 1.21 (d, 7.0) |
| 2MB-2′   | 2.52 (overlap) | 2.55 (m) | 2.26 (m) | 2.46 (m) | 2.45 (m) | 2.41 (m) | 2.22 (q, 7.0) | 2.22 (q, 7.0) |
| 2MB-3′   | 1.57 (m) | 1.72 (m) | 1.61 (m) | 1.75 (m) | 1.39 (m) | 1.59 (m) | 1.51 (m) | 1.70 (m) |
| 2MB-4′   | 1.12 (d, 7.0) | 1.22 (d, 7.0) | 1.04 (d, 7.0) | 1.18 (d, 7.0) | 1.17 (d, 7.0) | 1.12 (d, 7.0) | 1.04 (d, 7.0) | 1.21 (d, 7.0) |
| 2MB-2″   | 2.41 (m) | 2.56 (m) | 2.46 (m) | 2.48 (q, 7.0) | 2.48 (q, 7.0) |
| 2MB-3″   | 1.43 (m) | 1.59 (m) | 1.59 (m) | 1.76 (m) | 1.51 (m) | 1.70 (m) | 1.53 (m) | 1.70 (m) |
| 2MB-4″   | 0.89 (t, 7.4) | 1.01 (t, 7.4) | 0.95 (t, 7.4) | 0.94 (t, 7.4) | 0.88 (t, 7.4) | 0.86 (t, 7.4) |
| 2MB-5″   | 1.13 (d, 7.0) | 1.22 (d, 7.0) | 1.18 (d, 7.0) | 1.10 (d, 7.0) | 1.10 (d, 7.0) |
| Ac-2     | 1.90 (s) | 2.00 (s) | 2.04 (s) | 1.91 (s) | 1.99 (s) | 1.89 (s) |
| Ac-2′    | 1.91 (s) |
Table 2. The 150 MHz $^{13}$C-NMR data 1–8 (in CD$_3$OD; $\delta$ in ppm, $J$ in Hz).

| Position | 1     | 2     | 3     | 4     | 5     | 6     | 7     | 8     |
|----------|-------|-------|-------|-------|-------|-------|-------|-------|
| 1        | 72.5  | 72.8  | 73.3  | 72.7  | 70.6  | 72.1  | 72.3  | 74.2  |
| 2        | 71.0  | 70.6  | 70.2  | 70.4  | 73.3  | 72.4  | 71.7  | 73.0  |
| 3        | 69.8  | 69.8  | 69.6  | 69.7  | 72.4  | 69.9  | 72.6  | 71.5  |
| 4        | 72.3  | 72.7  | 70.8  | 70.8  | 72.6  | 72.0  | 71.1  | 73.9  |
| 5        | 72.3  | 72.2  | 72.3  | 72.8  | 72.6  | 72.0  | 74.5  | 74.6  |
| 6        | 73.9  | 73.7  | 71.6  | 71.6  | 76.6  | 75.9  | 70.6  | 70.9  |
| 2MB-1    | 177.5 | 177.2 | 176.6 | 177.2 | 177.6 | 177.6 | 178.2 | 177.5 |
| 2MB-2    | 42.5  | 42.6  | 42.4  | 42.2  | 42.4  | 42.2  | 42.4  | 42.2  |
| 2MB-3    | 27.8  | 27.9  | 27.5  | 27.7  | 27.5  | 27.7  | 28.0  | 27.7  |
| 2MB-4    | 11.9  | 12.0  | 12.0  | 11.8  | 11.9  | 11.8  | 11.8  | 11.8  |
| 2MB-5    | 17.0  | 17.4  | 17.0  | 17.0  | 16.8  | 16.8  | 17.4  | 17.4  |
| 2MB-1′   | 177.2 | 177.0 | 176.6 | 177.4 | 177.4 | 177.9 | 176.9 |       |
| 2MB-2′   | 42.6  | 42.6  | 42.1  | 42.5  | 42.6  | 42.3  | 42.2  |       |
| 2MB-3′   | 27.9  | 27.9  | 27.5  | 27.7  | 27.9  | 27.8  | 27.3  |       |
| 2MB-4′   | 11.9  | 12.0  | 11.8  | 11.9  | 12.0  | 11.8  | 11.8  |       |
| 2MB-5′   | 17.3  | 17.4  | 16.7  | 16.9  | 17.4  | 16.9  | 16.7  |       |
| Ac-1     | 171.2 | 171.9 | 171.7 | 171.1 | 172.1 | 171.8 |       |       |
| Ac-2     | 20.6  | 20.7  | 20.9  | 20.5  | 20.8  | 20.8  |       |       |
| Ac-1′    | 171.1 |       |       |       |       |       |       |       |
| Ac-2′    | 20.6  |       |       |       |       |       |       |       |
| iBu-1    | 177.8 | 177.9 |       |       |       |       | 177.8 |       |
| iBu-2    | 35.1  | 35.2  | 35.2  |       |       |       |       | 35.2  |
| iBu-3    | 19.1  | 19.2  |       |       |       |       |       | 19.0  |
| iBu-4    | 19.3  | 19.5  |       |       |       |       |       | 19.6  |
| iBu-1′   | 177.1 |       |       |       |       |       |       |       |
| iBu-2′   | 35.1  |       |       |       |       |       |       |       |
| iBu-3′   | 19.0  |       |       |       |       |       |       |       |
| iBu-4′   | 19.1  |       |       |       |       |       |       |       |

In the $^1$H–$^1$H COSY (Figure 2) and HMBC spectra, the cross-peaks of H-1/H-2/H-3/H-4/H-5/H-6 were deduced to be one cyclohexane structure. The proton signals at $\delta$H 1.90 (3H, s) correlated with the carbon signal at $\delta$C 171.2, suggesting that there was one acetate moiety (Ac); the proton signals at $\delta$H 1.13 (3H, d, $J = 7.0$ Hz) and 1.13 (3H, d, $J = 7.0$ Hz) correlated with the carbon signal at $\delta$C 171.2, suggesting that there was one acetate moiety (Ac); the proton signals at $\delta$H 2.41 (1H, q, $J = 7.0$ Hz), 1.46 (1H, m), 1.64 (1H, m), and 1.12 (3H, dd, $J = 12.2, 7.0$ Hz) correlated with the carbon signal at $\delta$C 177.5, with the cross-peaks of H$_{\text{2MB-3'}}$/H$_{\text{2MB-2'}}$/H$_{\text{2MB-4'}}$/H$_{\text{2MB-5'}}$ suggesting that there was a 2-methylbutyroyloxy moiety (2MB). The NMR data were compared with those in the literature, showing that these fragments were in accordance with the findings of previous studies [18,19]. The proton signals at $\delta$H 2.52 (1H, overlap), 1.57 (1H, m), 1.72 (1H, m), and 1.20 (1H, d, $J = 7.0$ Hz) correlated with the carbon signal at $\delta$C 177.2, with the cross-peaks of H$_{\text{2MB-3'}}$/H$_{\text{2MB-2'}}$/H$_{\text{2MB-4'}}$/H$_{\text{2MB-5'}}$ suggesting that there was a 2-methylbutyroyloxy moiety, 2MB. The correlation from H-1 to C-2MB indicated that the 2MB was attached to C-1; the correlation from H-3 to C-2MB$′$ indicated that the 2MB$′$ was attached to C-3; the correlation from H-2 to C-Ac indicated that the Ac was attached to C-2; the correlation from H-4 to C-iBu indicated that the iBu was attached to C-4. Through comparison with the literature [20], we found that the coupling patterns of six oxygenated methine protons in 1 included two axial/axial and axial/equatorial couplings with small $J$ values of 2.8 Hz, as well as trans-diaxial couplings with large $J$ values of 10.0. The coupling constants of 1 indicated the presence of the following: H-1 axial at $\delta$H 5.34
Compound 2 was obtained as a colorless solid. Its molecular formula, C_{21}H_{34}O_{10}, was determined by positive HR-ESI-MS at m/z 464.2498 [M + NH₄]^+ (calcld. 464.2496) with five degrees of unsaturation. The downfield chemical shifts of H-1 at δ_{H} 5.33 (1H, t, J = 10 Hz), H-2 at δ_{H} 5.08 (1H, dd, J = 10.0, 2.8 Hz), H-3 at δ_{H} 5.55 (1H, t, J = 10.0 Hz), H-4 at δ_{H} 4.89 (1H, overlap), H-5 at δ_{H} 4.89 (1H, t, J = 10.0 Hz), and H-6 at δ_{H} 3.56 (1H, t, J = 10 Hz) also suggested that 2 possesses a 1,2,3,4-tetra-substituted inositol ring as in 1. Through ¹H-¹H COSY and HMBC (Figure 3) spectra, the correlation from H-1 to C-iBu indicated that the iBu was attached to C-1; the correlation from H-2 to C-iBu indicated that the iBu was attached to C-2; the correlation from H-3 to C-2MB indicated that the 2MB was attached to C-3; the correlation from H-4 to C-Ac indicated that the Ac was attached to C-4. The relative configuration was determined by the same method as that used for 1. The NOESY correlations of H-1/H-5 demonstrated that the relative configuration of H-1/H-5 was determined as α. Therefore, compound 2 was determined to be myoinositol-1,3-(2-methylbutyrate)-2-acetate-4-isobutryloxy, and was named solsurinositol B.

Compound 3 was obtained as a colorless solid. Its molecular formula, C_{25}H_{40}O_{11}, was determined by positive HR-ESI-MS at m/z 534.2916 [M + NH₄]^+ (calcld. 534.2914) with six degrees of unsaturation. The NMR data of 3 were similar to those of 1 (Tables 1 and 2), which meant that they had the same cyclohexane structure. The main difference was the substituent patterns of the inositol ring. Through ¹H-¹H COSY and HMBC (Figure 4) spectra, the correlation from H-1 to C-Ac indicated that the Ac was attached to C-1; the correlation from H-2 to C-2MB indicated that the 2MB was attached to C-2; the correlation from H-3 to C-2MB′ indicated that the 2MB′ was attached to C-3; the correlation from H-4 to C-iBu...
to C-Ac′ indicated that the Ac′ was attached to C-4; the correlation from H-5 to C-2MB′ indicated that the 2MB′ was attached to C-5. The relative configuration was determined by the same method as that used for 1. The configurations of H-1 at $\delta_{\text{H}}$ 5.41 (1H, td, $J = 10.0, 5.2$ Hz) and H-5 at $\delta_{\text{H}}$ 5.41 (1H, td, $J = 10.0, 5.2$ Hz) were defined by coupling constant as β. Therefore, compound 3 was determined to be myoinositol-1,4-acetate-2,3,5-(2-methylbutyrate), and was named solsurinositol C.

Compound 4 was obtained as a colorless solid. Its molecular formula, $C_{27}H_{44}O_{11}$, was determined by positive HR-ESI-MS at $m/z$ 562.3228 [M + NH$_4$]$^+$ (calcld. 562.3227) with six degrees of unsaturation. The NMR data of 4 (Tables 1 and 2) were similar to those of 1, which meant that they had the same cyclohexane structure. In $^1$H-$^1$H COSY and HMBC, the correlation from H-1 to C-2MB indicated that the 2MB was attached to C-1; the correlation from H-2 to C-2MB′ indicated that the 2MB′ was attached to C-2; the correlation from H-3 to C-2MB″ indicated that the 2MB″ was attached to C-3; the correlation from H-4 to C-Ac indicated that the Ac was attached to C-4; the correlation from H-5 to C-iBu indicated that the iBu was attached to C-5. The NMR data were compared with those in the literature, showing that these fragments were consistent with those that had been found previously [21]. The relative configuration was determined by the same method as that used for 1. The configurations of H-1 and H-5 were defined by coupling constant $\delta_{\text{H}}$ at 5.43 (1H, t, $J = 10.0$ Hz) and 5.38 (1H, t, $J = 10.0$ Hz) as β. Therefore, compound 4 was myoinositol-1,2,3-(2-methylbutyrate)-4-acetate-5-isobutyroyloxy, and was named solsurinositol D.

Compound 5 was obtained as a colorless solid. Its molecular formula, $C_{21}H_{36}O_9$, was determined by positive HR-ESI-MS at $m/z$ 433.2424 [M + H]$^+$ (calcld. 433.2438) with four degrees of unsaturation. $^1$H and $^1$C NMR spectra were close to compound 1 with the presence of one cyclohexane structure. The main difference was the substituent pattern and number. In $^1$H-$^1$H COSY and HMBC (Figure 4) spectra, the correlation from H-2 to C-2MB indicated that the 2MB was attached to C-2; the correlation from H-3 to C-2MB′ indicated that the 2MB′ was attached to C-3; the correlation from H-6 to C-2MB″ indicated that the 2MB″ was attached to C-6 [22]. The coupling patterns of six oxygenated methine protons were close to 1. Therefore, compound 5 was myoinositol-2,3,6-(2-methylbutyrate), and was named solsurinositol E.

Compound 6 was obtained as a colorless solid. Its molecular formula, $C_{18}H_{30}O_9$, was determined by positive HR-ESI-MS at $m/z$ 408.2228 [M + NH$_4$]$^+$ (calcld. 408.2234) with four degrees of unsaturation. The NMR data of 6 were similar to those of 1, which meant that they had a similar cyclohexane structure. In $^1$H-$^1$H COSY and HMBC (Figure 5), the correlation from H-2 to C-2MB indicated that the 2MB was attached to C-2; the correlation from H-3 to C-2MB′ indicated that the 2MB′ was attached to C-3; the correlation from H-4 to C-Ac indicated that the Ac was attached to C-4. The NOESY (Figure 5) correlations demonstrated that the relative configurations of H-2/H-4 and H-6 were determined as β. Based on the above $^1$H NMR and $^1$C NMR spectrum data, the structure of compound 6 was similar to that of 1β-acetate 2α-methylbutanoate 3α-methylbutanoate, except for the relative configuration [21]. Through the analysis of the compound, it was found that the
configuration of the fourth position of the compound was opposite. Therefore, compound 6 was myoinositol-2,3-(2-methylbutyrate)-4-acetate, and was named solsurinositol F.

\[
\text{COSY} \quad \text{HMBC} \quad \text{NOESY}
\]

**Figure 5.** \(^1\)H-\(^1\)H COSY, key HMBC, and NOE correlations of compound 6.

Compound 7 was obtained as a colorless solid. Its molecular formula, \(\text{C}_{21}\text{H}_{36}\text{O}_{9}\), was determined by positive HR-ESI-MS at \(m/z\) 408.2249 [M + NH\(_4\)]\(^+\) (calcd. 408.2228) with four degrees of unsaturation. The \(^1\)H and \(^13\)C NMR spectra were close to compound 1 with the presence of one six-membered ring structure. The main difference was the side connections. In \(^1\)H-\(^1\)H COSY and HMBC (Figure 6) spectra, the correlation from H-1 to C-2MB indicated that the 2MB was attached to C-1; the correlation from H-2 to C-Ac indicated that the Ac was attached to C-2; the correlation from H-3 to C-2MB' indicated that the 2MB' was attached to C-3 [23]. The coupling patterns of six oxygenated methine protons were close to those of 1. Therefore, compound 7 was myoinositol-1,3-(2-methylbutyrate)-2-acetate, and was named solsurinositol G.

\[
\text{COSY} \quad \text{HMBC} \quad \text{COSY} \quad \text{HMBC}
\]

**Figure 6.** \(^1\)H-\(^1\)H COSY, key HMBC correlations of compounds 7 and 8.

Compound 8 was obtained as a colorless solid. Its molecular formula, \(\text{C}_{21}\text{H}_{36}\text{O}_{9}\), was determined by positive HR-ESI-MS at \(m/z\) 450.2715 [M + NH\(_4\)]\(^+\) (calcd. 450.2703) with four degrees of unsaturation. \(^1\)H and \(^13\)C NMR spectra were close to compound 1 with the presence of one cyclohexane structure. The main difference was the substituent pattern and number. In \(^1\)H-\(^1\)H COSY and HMBC (Figure 6) spectra, the correlation from H-2 to C-2MB indicated that the 2MB was attached to C-1; the correlation from H-3 to C-2MB' indicated that the 2MB' was attached to C-3; the correlation from H-4 to C-2MB'' indicated that the 2MB'' was attached to C-4. The coupling patterns of six oxygenated methine protons were close to 1. Therefore, compound 8 was myoinositol-2,3,6-(2-methylbutyrate), and was named solsurinositol H.

Using the CCK8 method, the in vitro cytotoxicity of all isolated compounds on BV2 cells was evaluated in vitro. The results are listed in Table 3. Compounds 1–8 were not significantly cytotoxic to BV2 cells (IC\(_{50} > 100 \mu\text{M}\)).
Inositols were shown to have anti-inflammatory activity in the literature, which was tested against LPS-induced NO (nitric oxide) production in RAW 264.7 macrophages and BV2 microglia [22,24]. Our study also supported previous results. In this study, isolated compounds 1–8 were examined for their inhibition of NO production in LPS-stimulated BV2 cells (Table 4). Compounds 3 and 4 showed very weak NO-production-inhibition activities, with IC_{50} > 100 µM. Compounds 1, 2, 6, and 8 exhibited inhibitory activities, with IC_{50} values of 24.27 ± 1.82, 31.66 ± 2.71, 23.31 ± 0.74, and 31.03 ± 0.92 µM, respectively. Compounds 5 (IC_{50} = 11.21 ± 0.14 µM) and 7 (IC_{50} = 14.5 ± 1.22 µM) had good anti-inflammatory activity in vitro. Inositol was reported to be effective in treating central nervous system disorders such as depression, Alzheimer’s disease, and obsessive–compulsive disorder in [25,26]. Our experimental results showed that compounds 5 and 7 were promising for the treatment of neuroinflammation. Although it was reported that Solanum has anti-inflammatory effects, and the steroids and flavonoids were considered to be the active components [27–29], our study found that inositol derivatives isolated from this plant also had potential anti-inflammatory effects.

### Table 3. Cytotoxic activities of compounds 1–8.

| No. | IC_{50} (µM) | No. | IC_{50} (µM) |
|-----|-------------|-----|-------------|
| 1   | >100        | 5   | >100        |
| 2   | >100        | 6   | >100        |
| 3   | >100        | 7   | >100        |
| 4   | >100        | 8   | >100        |

### Table 4. Inhibitory effects of compounds 1–8 on NO in LPS-induced BV-2.

| No. | IC_{50} (µM) | No. | IC_{50} (µM) |
|-----|-------------|-----|-------------|
| 1   | 24.27 ± 1.82| 6   | 23.31 ± 0.74|
| 2   | 31.66 ± 2.71| 7   | 14.50 ± 1.22|
| 3   | >100        | 8   | 31.03 ± 0.92|
| 4   | >100        | NMMA| 1.67 ± 0.24 |
| 5   | 11.21 ± 0.14|     |             |

### 3. Materials and Methods

#### 3.1. General Experimental Procedures

HR-ESI-MS spectra were selected on a Thermo Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). NMR spectra were used in a Bruker DPX-600 spectrometer (Bruker Company Ltd, Karlsruhe, Germany) with TMS as an internal standard. Optical rotation was measured on the Jasco P-2000 digital polarizer. Preparative HPLC was measured by LC-20AR pump and RID-20A detector (flow rate: 5 mL/min) by a C18 column (5 µm, 20 × 250 mm, 5 mL/min, Shimadzu, Japan). Column chromatography was carried out on silica gel (80–100 mesh and 200–300 mesh, Shanghai Titan Scientific Co, Shanghai, China) and ODS (Octadecylsilyl) (YMC Company Ltd., Kyoto, Japan).

#### 3.2. Plant Material

The leaves of *Solanum capsicoides* were collected from Kunming (Yunnan Province) in 2020. We harvested in August when the leaves were growing most vigorously. The plant sample was identified by Professor Rui-Feng Fan of the Heilongjiang University of Chinese Medicine, and its certificate specimen (No. 20200826) is now stored in the Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education of Heilongjiang University of Chinese Medicine.
3.3. Extraction and Isolation

The dried leaves of *S. capsicoides* (20.0 kg) were refluxed 3 times with 70% EtOH for 2 hours each time, to obtain a crude extract (6.0 kg) after removal of the solvent under vacuum. The 3.0 kg crude extract was eluted through the resin of HP-20 to obtain water (749.0 g), 30% ethanol (343.0 g), and 95% ethanol extracts (423.0 g).

The 95% EtOH extract was fractionated by a silica gel column (200–300 mesh) using CHCl₃/MeOH in a gradient (10:0 to 0:10) to yield eight fractions (Fr. A—H). Fr. C (23.9 g) was separated by MCI (Middle Chromatogram Isolated) chromatography, and eluted with CH₃OH/H₂O (1:9–10:0). Through TLC analysis, 22 sub-fractions were obtained. Fr. C-14 was purified by preparative HPLC (MeOH/H₂O 65%) to obtain compound 1 (19.9 mg, t<sub>R</sub> = 24.8 min) and compound 3 (9.3 mg t<sub>R</sub> = 33.27 min). Fr. C-16 was purified by preparative HPLC (MeOH/H₂O 75%) to obtain compound 4 (40.4 mg, t<sub>R</sub> = 28.6 min). The Fr. D (21.6 g) was dealt with MCI chromatography and elution with CH₃OH/H₂O (1:9–10:0) in sequence to obtain 20 sub-fractions. Fr. D-12 was purified by preparative HPLC (MeOH/H₂O 68%) to obtain compound 2 (14.4 mg, t<sub>R</sub> = 45.3 min) and compound 5 (24.0 mg, t<sub>R</sub> = 50.7 min). The Fr. E (35.0 g) was dealt with MCI chromatography and eluted with CH₃OH/H₂O (1:9–10:0) in sequence to obtain 50 sub-fractions. Fr. E-1 (4.8 g) was dealt with ODS chromatography and eluted with CH₃OH/H₂O (1:9–10:0) in sequence to obtain 3 sub-fractions. Fr. E-1 (4.8 g) was dealt with ODS chromatography and eluted with CH₃OH/H₂O (1:9–10:0) in sequence to obtain 20 sub-fractions. Fr. D-12 was purified by preparative HPLC (MeOH/H₂O 65%) to obtain compound 7 (11.9 mg, t<sub>R</sub> = 20.6 min). Fr. E1-35 was purified by preparative HPLC (MeOH/H₂O 65%) to obtain compound 8 (12.2 mg, t<sub>R</sub> = 15.9 min).

**Solsurinositol A (1)**

Colorless solid; [α]<sub>D</sub>+5.2 (c 1.00, MeOH); ¹H NMR (methanol-d₄, 600 MHz): (Table 1); ¹³C NMR (methanol-d₄, 150 MHz): (Table 2); HR-ESI-MS m/z 478.2656 [M + NH₄]<sup>+</sup> (calcd. for C₂₂H₄₀NO₁₀, 478.2652).

**Solsurinositol B (2)**

Colorless solid; [α]<sub>D</sub>+44.3 (c 1.00, MeOH); ¹H NMR (methanol-d₄, 600 MHz): (Table 1); ¹³C NMR (methanol-d₄, 150 MHz): (Table 2); HR-ESI-MS m/z 464.2496 [M + NH₄]<sup>+</sup> (calcd. for C₂₁H₃₈NO₁₀, 464.2496).

**Solsurinositol C (3)**

Colorless solid; [α]<sub>D</sub>+10.6 (c 1.00, MeOH); ¹H NMR (methanol-d₄, 600 MHz): (Table 1); ¹³C NMR (methanol-d₄, 150 MHz): (Table 2); HR-ESI-MS m/z 534.2916 [M + NH₄]<sup>+</sup> (calcd. for C₂₅H₄₄NO₁₁, 534.2914).

**Solsurinositol D (4)**

Colorless solid; [α]<sub>D</sub>+37.8 (c 1.00, MeOH); ¹H NMR (methanol-d₄, 600 MHz): (Table 1); ¹³C NMR (methanol-d₄, 150 MHz): (Table 2); HR-ESI-MS m/z 562.3228 [M + NH₄]<sup>+</sup> (calcd. for C₂₇H₄₈NO₁₁, 562.3227).

**Solsurinositol E (5)**

Colorless solid; [α]<sub>D</sub>+36.4 (c 1.00, MeOH); ¹H NMR (methanol-d₄, 600 MHz): (Table 1); ¹³C NMR (methanol-d₄, 150 MHz): (Table 2); HR-ESI-MS m/z 433.2438 [M + H]<sup>+</sup> (calcd. for C₂₁H₃₀O₄, 433.2438).

**Solsurinositol F (6)**

Colorless solid; [α]<sub>D</sub>+5.58 (c 1.00, MeOH); ¹H NMR (methanol-d₄, 600 MHz): (Table 1); ¹³C NMR (methanol-d₄, 150 MHz): (Table 2); HR-ESI-MS m/z 408.2228 [M + NH₄]<sup>+</sup> (calcd. for C₁₈H₃₄NO₉, 408.2234).
Solsurinositol G (7)
Colorless solid; $[\alpha]_{D}^{22} +16.1$ (c 1.00, MeOH); $^1$H NMR (methanol-d$_4$, 600 MHz): (Table 1); $^{13}$C NMR (methanol-d$_4$, 150 MHz): (Table 2); HR-ESI-MS $m/z$ 408.2249 [M + NH$_4$]$^+$ (calcd. for C$_{18}$H$_{34}$NO$_9$, 408.2234).

Solsurinositol H (8)
Colorless solid; $[\alpha]_{D}^{22} +2.76$ (c 1.00, MeOH); $^1$H NMR (methanol-d$_4$, 600 MHz): (Table 1); $^{13}$C NMR (methanol-d$_4$, 150 MHz): (Table 2); HR-ESI-MS $m/z$ 450.2715 [M + NH$_4$]$^+$ (calcd. for C$_{21}$H$_{40}$NO$_9$, 450.2703).

3.4. Bioactive Activity
The cytotoxicity assay was performed with a modified CCK8 method. First, BV2 microglial cells were cultured with 96-well microplates (10$^4$ cells/well in 100 µL medium) for 24 h. Then, the cells were treated with different concentrations (5, 10, 30, 50, 100, 200 µM) of compounds. After the cells were incubated for 24 h, added 10 µL CCK8 solution to each well and incubated for 2 h in a 5% CO$_2$ humidifier at 37 °C. The absorbance was recorded at 450 nm with a microplate reader (BioTek Company, Winooski, VT, USA), repeating three times, and its IC$_{50}$ value was calculated.

BV2 microglial cells were cultured in DMEM containing 10% fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin at 37 °C with 5% CO$_2$. Then, the cells were placed in 96-well microplates and treated with different compounds at 1–8 concentrations (5, 10, 30, 50, 100, 200 µM) for 1 h. Next, the cells were treated with 1 µg/mL LPS for 24 h to detect the NO (nitric oxide) levels in culture supernatants. After the Griess reaction (incubated at 37 °C with 5% CO$_2$ for 0.5 h), the absorbance of cells was measured with a microplate reader (BioTek Company, Winooski, VT, USA) at 450 nm, repeated three times, and its IC$_{50}$ value was calculated.

4. Conclusions
In summary, eight new inositol derivatives were isolated from S. capsicoides, named solsurinositols A–H (1–8). Their structures were determined by extensive spectroscopic analysis, including 1D, 2D NMR, and HR-ESI-MS. The inflammation model was established by LPS-induced BV2 microglia, and the anti-inflammatory effects of all compounds (1–8) were evaluated. Except for compounds 3 and 4, the compounds had varying degrees of anti-inflammatory effects, with IC$_{50}$ values ranging from 11 to 35 µM. Compounds 5 (IC$_{50} = 11.21 \pm 0.14$ µM) and 7 (IC$_{50} = 14.5 \pm 1.22$ µM) had potential anti-inflammatory activity. Inhibition of inflammation caused by hyperactivation of microglia is one of the effective strategies for treating neurodegenerative diseases. Therefore, compounds 5 and 7 are promising for the treatment of neuroinflammation. It is hoped that our study can provide a new direction for the study and application of S. capsicoides. We look forward to investigating the exact mechanism of action in further studies.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/molecules27186063/s1, Figures S1–S64: The HR-ESI-MS, $^1$H NMR, $^{13}$C NMR, DEPT, $^1$H-$^1$H COSY, HSQC, HMBC, NOESY spectrum of compound 1–8; Figure S65: The HPLC spectrum of 1–8.

Author Contributions: Data curation, Y.S.; funding acquisition, conceptualization and methodology, H.-X.K. and B.-Y.Y.; investigation, H.W.; validation, S.-Y.W. and Y.-K.J.; writing—original draft preparation, X.M.; writing—review and editing, Y.L., A.M.A. and A.N. All authors have read and agreed to the published version of the manuscript.

Funding: This work was financially supported by the Heilongjiang Touyan Innovation Team Program; the National Key Research and Development Project (2018YFC1707100); the China Postdoctoral Science Foundation (2018M631978); the Excellent Youth Project of Heilongjiang Natural Science Foundation (YQ2019H029).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
Data Availability Statement: Data are contained within the article and supplementary material.

Acknowledgments: We would like to express our gratitude to Fan Rui-Feng from the Heilongjiang University of Chinese Medicine for his contributions to the identification of plants.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are available from the authors.

References

1. Siracusa, L.; Napoli, E.; Ruberto, G. Novel Chemical and Biological Insights of Inositol Derivatives in Mediterranean Plants. *Molecules* **2022**, *27*, 1525. [CrossRef] [PubMed]

2. Michell, R.H. Inositol derivatives: Evolution and functions. *Nat. Rev. Mol. Cell. Biol.* **2008**, *9*, 151–161. [CrossRef] [PubMed]

3. Ratiu, I.A.; Al-Suod, H.; Ligor, M.; Ligor, T.; Krakowska, A.; Górecki, R.; Buszewski, B. Simultaneous Determination of Cyclitols and Sugars Following a Comprehensive Investigation of 40 Plants. *Food Anal. Methods* **2019**, *12*, 1466–1478. [CrossRef]

4. Papaleo, E.; Unfer, V.; Baillargeon, J.P.; Chiu, T.T. Contribution of myo-inositol to reproduction. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **2009**, *147*, 120–123. [CrossRef] [PubMed]

5. Crote, M.L.; Soulage, C.O. Potential role and therapeutic interests of myo-inositol in metabolic diseases. *Biochimie* **2013**, *95*, 1811–1827. [CrossRef]

6. Simões, I.O.; Conceição-Filho, G.; Ribeiro, T.S.; Jesus, A.M.; Fregoneze, J.B.; Silva, A.Q.G.; Petreanu, M.; Cechinel-Filho, V.; Niero, R.; Niero, H.; et al. Evidences of antihypertensive potential of extract from *Solanum capsicoides* All. in spontaneously hypertensive rats. *Phytomedicine* **2016**, *23*, 498–508. [CrossRef]

7. Petreanu, M.; Maia, P.; da Rocha Pittarello, J.L.; Monache, F.D.; Perez, A.L.; Solano-Arias, G.; Filho, V.C.; de Souza, M.M.; Niero, R. Antidepressant-like effect and toxicological parameters of extract and withanolides isolated from aerial parts of *Solanum capsicoides* All. (Solanaceae). *Naunyn-Schmiedeberg’s Arch. Pharmacol.* **2019**, *392*, 979–990. [CrossRef]

8. Huque, A.; Biswas, S.; Abdullah-Al-Mamun, M.; Bhuiyan, J.Y.; ur Rashid, M.H.; Jahan, A. Analgesic, anti-inflammatory and anxiolytic activity evaluation of methanolic extract of Solanum surattense leaf in Swiss Albino mice model. *Int. J. Pharm. Clin. Res.* **2015**, *7*, 68–76.

9. Vijay Amirtharaj, L.; Srinivasan, N.; Sireesha Abburi Karthikeyan, K.; Mahalaxmi, S. Evaluating the Analgesic Efficacy of Solanum surattense (Herbal Seed Extract) in Relieving Pulpal Pain-An In-vivo Study. *Dentistry* **2015**, *5*, 4. [CrossRef]

10. Chen, B.-W.; Chen, Y.-Y.; Lin, Y.-C.; Huang, C.-Y.; Uvarani, C.; Hwang, T.-L.; Chiang, M.Y.; Liu, H.-Y.; Sheu, J.-H. Capsisteroids A–F, withanolides from the leaves of *Solanum capsicoides*. *RSC Adv.* **2015**, *5*, 88841–88847. [CrossRef]

11. Lu, Y.; Luo, J.; Kong, L. Steroidal alkaloid saponins and steroidal saponins from *Solanum Surattense*. *Phytochemistry* **2011**, *72*, 668–673. [CrossRef] [PubMed]

12. Nawaz, H.; Ahmed, E.; Sharif, A.; Arshad, M.; Batool, N.; Rasool, M.A.; Mukhtar Ul, H. Two New Steroidal Glycosides from *Solanum surattense*. *Chem. Nat. Compd.* **2014**, *49*, 1091–1094. [CrossRef]

13. Wang, H.; Liu, Y.; Jang, Y.-K.; Wang, S.-Y.; Li, X.-M.; Pan, J.; Guan, W.; Algradi, A.M.; Kuang, H.-X.; Yang, B.-Y. Phenylpropanoids from *Solanum capsicoides* and their anti-inflammatory activity. *J. Asian Nat. Prod. Res.* **2022**, 1–7. [CrossRef]

14. Jie-Hui, L.Y.; Yin, H.L.; Dong, J.X. Phenylpropanoids from *Solanum Surattense*. *Mil. Med. Sci.* **2013**, *37*, 130–134. [CrossRef]

15. Kong, J.; Du, Z.H.; Dong, L. Pinitol Prevents Lipopolysaccharide (LPS)-Induced Inflammatory Responses in BV2 Microglia Mediated by TREM2. *Neurotox. Res.* **2020**, *38*, 96–104. [CrossRef] [PubMed]

16. Kallio, H.; Lassila, M.; Jarvenpaa, E.; Haraldsson, G.; Jonsdottir, S.; Yang, B. Inositol and methylinositols in sea buckthorn (*Hippophaë rhamnoides*) berries. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* **2009**, *877*, 1426–1432. [CrossRef]

17. Abreu, P.; Relva, A. Carbohydrates from *Detarium microcarpum* bark extract. *Carbohydr. Res.* **2002**, *337*, 1663–1666. [CrossRef]

18. Wu, J.W.; Tang, C.P.; Yao, S.; Zhang, L.; Ke, C.Q.; Feng, L.; Lin, G.; Ye, Y. Anti-inflammatory Inositol Derivatives from the Whole Plant of *Inula capra*. *J. Nat. Prod.* **2015**, *78*, 2323–2338. [CrossRef]

19. Karayev, E.; Herbette, G.; Di Giorgio, C.; Chiffolleau, P.; Roux, D.; Sallanon, H.; Ollivier, E.; Elias, R.; Baghdikian, B. New sesquiterpene acid and inositol derivatives from *Inula montana* L. *Fitoterapia* **2017**, *120*, 79–84. [CrossRef]

20. Fortuna, A.M.; Juarez, Z.N.; Bach, H.; Nemataollah, A.; Av-Gay, Y.; Sanchez-Arceola, E.; Catalan, C.A.; Turbay, S.; Hernandez, L.R. Antimicrobial activities of sesquiterpene lactones and inositol derivatives from *Hymenoxys Robusta*. *Phytochemistry* **2011**, *72*, 2413–2418. [CrossRef]

21. Gao, F.; Wang, H.P.; Mabry, T.J. Sesquiterpene lactone aglycones and glycosides and inositol derivatives from *Hymenoxys biennis*. *Phytochemistry* **1990**, *29*, 3875–3880. [CrossRef]

22. Nguyen, K.V.; Ho, D.V.; Nguyen, H.M.; Do, T.T.; Phan, K.V.; Morita, H.; Heinamaki, J.; Raal, A.; Nguyen, H.T. Chiro-Inositol Derivatives from Chiosocheton paniculatus Show Inhibition of Nitric Oxide Production. *J. Nat. Prod.* **2020**, *83*, 1201–1206. [CrossRef] [PubMed]

23. Nguyen, H.T.; Tran, L.T.T.; Ho, D.V.; Phan, K.V.; Raal, A.; Morita, H. Three new inositol derivatives from Chiosocheton paniculatus. *Tetrahedron Lett.* **2019**, *60*, 1841–1844. [CrossRef]

24. Gambioli, R.; Montanino Oliva, M.; Nordio, M.; Chieffari, A.; Puliani, G.; Unfer, V. New Insights into the Activities of D-Chiro-Inositol: A Narrative Review. *Biomedicines* **2021**, *9*, 1378. [CrossRef] [PubMed]
25. Colodny, L.; Hoffman, R.L. Inositol—Clinical applications for exogenous use. *Altern. Med. Rev.* 1998, 3, 432–447. [PubMed]
26. Fux, M.; Levine, J.; Aviv, A.; Belmaker, R.H. Inositol treatment of obsessive-compulsive disorder. *Am. J. Psychiatry* 1996, 153, 1219–1221. [CrossRef]
27. Raju, K.; Anbuganapathi, G.; Gokulakrishnan, V.; Rajkapoor, B.; Jayakar, B.; Manian, S. Effect of Dried Fruits of *Solanum nigrum* LINN against CCl$_4$-Induced Hepatic Damage in Rats. *Biol. Pharm. Bull.* 2003, 26, 1618–1619. [CrossRef]
28. Jarald, E.E.; Edwin, S.; Saini, V.; Deb, L.; Gupta, V.B.; Wate, S.P.; Busari, K.P. Anti-inflammatory and anthelmintic activities of *Solanum khasianum* Clarke. *Nat. Prod. Res.* 2008, 22, 269–274. [CrossRef]
29. Ndebia, E.J.; Kamgang, R.; Nkeh-Chunganganye, B.N. Analgesic and Anti-Inflammatory Properties of Aqueous Extract from Leaves of *Solanum Torvum* (Solanaceae). *Afr. J. Trad. CAM* 2007, 4, 240–244. [CrossRef]